BMEA News & Events

Biomea Fusion announced a research collaboration with the University of Leicester to evaluate its investigational menin inhibitor, icovamenib, in combination with semaglutide in obesity within the ongoing OPAL platform study. "We are excited to collaborate with Professor Davies, Professor Yates, and the team at the Leicester Diabetes Centre on this important addition to the OPAL platform study," said Thorsten Kirschberg, executive VP of research at Biomea Fusion. "Compelling preclinical data demonstrating synergistic effects between icovamenib and semaglutide gave us conviction that this combination has the potential to deliver meaningful benefits beyond weight loss alone." Enrollment is scheduled to begin in the third quarter of 2026, with the primary outcome assessment performed at week 24.

As of March 31, the company had cash, cash equivalents and restricted cash of $45.1M vs. $56.2M at previous quarter end. "Across our portfolio, we continue to execute with focus and discipline, with all of our key clinical programs progressing on track toward important upcoming milestones, while maintaining a disciplined approach to managing our cash burn," said interim CEO Mick Hitchcock. "The recent 52-week data from the Phase II COVALENT-112 clinical trial in type 1 diabetes further support targeting menin as a novel approach across both type 1 and type 2 diabetes, which offers a paradigm shift and differs materially from existing therapeutic approaches. We are building on these findings with plans to initiate an investigator-sponsored Phase II clinical trial in collaboration with leading academic institutions specializing in T1D. We believe this collaboration, alongside the continued advancement of our type 2 diabetes and obesity programs, positions Biomea to deliver meaningful data across multiple indications in 2026."